COMPLETE GENOMICS, INC. 
By Aug 25, 2011
Silicon Valley veteran Keith Raffel and diagnostics expert Dr. Jill Hagenkord bring experience in software, cloud computing and diagnostics to their newly-created positionsMOUNTAIN VIEW, Calif. — Aug. 25, 2011 — Complete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced it has appointed Keith Raffel as chief commercial officer (CCO) and Dr. Jill Hagenkord as chief medical officer (CMO). Both executives will support continued growth in the company’s service offerings and spearhead the development of new products to deliver high-quality, cost-effective genomic data and analysis.
As senior vice president and CCO, Raffel will focus on identifying new growth opportunities for Complete Genomics’ human genome sequencing services. Leveraging his background in cloud computing and software, Raffel will explore innovative ways to provide information and support that streamlines and advances the work of researchers and clinicians.
“We are delighted to have a visionary like Keith join our team and are looking forward to leveraging his expertise in product commercialization, cloud computing and software as our business continues to evolve and scale to meet customer needs,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. “Under Keith’s leadership, we plan to further our development of innovative and effective sequencing services that help researchers and clinicians increase their understanding of the genetic mechanisms underlying drug responses and complex diseases.”
Raffel founded and served as chairman and CEO of UpShot Corp., the first cloud-computing company in Silicon Valley. At UpShot, he designed the prototype for the company’s cloud-based CRM service and spearheaded the development of innovative products that were implemented by customers such as Xerox, Hewlett-Packard and Johnson & Johnson. He helped raise more than $60 million in financing before selling the business to Siebel Systems, where he remained on board as a group vice president. Raffel is also a best-selling novelist. He has a bachelor’s degree from Harvard College, a master’s degree from the University of Oxford and a law degree from Harvard Law School.
“I am bowled over by what the Complete Genomics team has done to define the complete human genome sequencing market and transform how researchers investigate new therapies for cancer and other conditions,” Raffel said. “Working with them to improve human health by providing information to prevent, diagnose and treat genetic diseases and conditions is a dream job.”
As CMO, Dr. Hagenkord will leverage her clinical diagnostics experience to expand the use of Complete Genomics’ human genome sequencing services for the translational medicine market and targeted clinical diagnostic development.
“The use of genomic data has enormous potential to help clinicians tailor treatment and care to the individual patient,” Dr. Reid said. “The addition of Jill to our team gives us an opportunity to build on our success and partnerships in the diagnostics market and in such critical areas as cancer treatment.”
Dr. Hagenkord comes to Complete Genomics from iKaryos Diagnostics, a clinically-focused cancer diagnostics company in Palo Alto, Calif., that operates in collaboration with Creighton University and Creighton Medical Laboratories in Omaha, Neb. While at iKaryos, Dr. Hagenkord also served as an associate professor at Creighton and director of molecular pathology and clinical genomics in its department of pathology. Before joining iKaryos, Dr. Hagenkord worked as a pathologist for Deltagen Inc., a provider of drug discovery tools for the biopharmaceutical industry. Dr. Hagenkord received her M.D. from Stanford University School of Medicine and did her residency training in pathology at the University of California at San Francisco and the University of Iowa. She completed fellowships in pathology and oncology informatics and molecular genetic pathology at the University of Pittsburgh.
“I am thrilled to join Complete Genomics as it reaches the intersection of genomic research and clinical medicine,” Dr. Hagenkord said. “Complete Genomics is poised to become the premier provider for clinicians looking to utilize the power of complete genome data to identify and treat diseases and different medical conditions.”
About Complete Genomics
Complete Genomics is the complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with its advanced informatics and data management software. Complete Genomics offers this solution as an innovative, end-to-end, outsourced service, CGA™ Service, which provides customers with ready-to-use data for genome-based research. Additional information can be found at http://www.completegenomics.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These statements relate to, among other forward-looking matters, our abilities to develop innovative and effective sequencing services that will help researchers and clinicians increase their understanding of the genetic mechanisms underlying drug responses and complex diseases; to expand the use of our human genome sequencing services for the translational medicine market and targeted clinical diagnostic development; and to become the premier provider for clinicians looking to utilize the power of genome data to identify and treat diseases and different medical conditions. Readers are cautioned that these forward-looking statements are based on management’s current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: uncertainties relating to our ability to develop new service offerings, to reduce the average cost of our sequencing service and to increase our production capabilities; risks relating to the emergence of competitive genome sequencing technologies; and risks relating to the growth of markets for analysis of genetic variation and biological function and the shift of these markets to complete human genome sequencing, our ability. More information on potential risks and uncertainties is included in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned “Risk Factors” in our Quarterly Report on Form 10-Q filed on Aug. 15, 2011. We disclaim any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.
# # #
